Sangamo Therapeutics, Inc.

Sangamo Therapeutics, Inc. is a clinical-stage biotechnology company specializing in genomic medicines. It generates revenue through its platform technologies in gene therapy, cell therapy, genome editing, and genome regulation. The company's offerings include zinc finger protein (ZFP) technology for modifying DNA sequences and increasing or decreasing gene expression. Its product pipeline consists of treatments for hemophilia A, Fabry disease, sickle cell disease, kidney transplant rejection, cancer, tauopathies, and synucleinopathies. Sangamo Therapeutics has established collaborative and strategic partnerships with leading biopharmaceutical companies, enabling it to advance its innovative therapies.

Products

• Gene therapy for hemophilia A

• Gene therapy for Fabry disease

• Cell therapy for sickle cell disease

• Chimeric antigen receptor for kidney transplant rejection

• Cell therapy for cancer

• Therapies for tauopathies and synucleinopathies